Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals ... of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the November 21st expiration. One of the key inputs that goes into the price an option ...

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Over the next few years, immuno ...

Regeneron has more growth opportunities ahead ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

While the stock is pricier compared to companies like Gilead Sciences and Regeneron Pharmaceuticals ... and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., ...